Literature DB >> 28341308

Biochemical characterization and stability of immune globulin intravenous 10% liquid (Panzyga®).

Christa Mersich1, Karin Ahrer2, Andrea Buchacher2, Thomas Ernegger2, Guido Kohla3, Christoph Kannicht3, Katharina Pock2, Jürgen Römisch2.   

Abstract

Panzyga® is a new glycine-formulated immune globulin intravenous 10% liquid for the treatment of patients suffering from immunodeficiencies and autoimmune diseases. Panzyga® is a high purity, native and functional IgG product with an IgG subclass distribution equivalent to normal plasma. The levels of hemagglutinins and accompanying plasma proteins (including IgA and IgM) are low. Potential procoagulant activity is not detectable. Functional activity of the IgG was demonstrated by opsonophagocytosis and receptor binding assays. Dynamic light scattering measurements and fluorescent dye binding were used to characterize the integrity of the IgG molecule. Panzyga® is stable under refrigerated storage for at least two years regarding all assessed physicochemical and functional parameters; it can also be stored at room temperature for at least twelve months within its total shelf-life.
Copyright © 2016 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  IVIG 10% liquid; Integrity; Panzyga(®); Purity; Safety; Stability

Mesh:

Substances:

Year:  2016        PMID: 28341308     DOI: 10.1016/j.biologicals.2016.10.003

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  2 in total

1.  Pathogen Safety of a New Intravenous Immune Globulin 10% Liquid.

Authors:  Kai Uwe Radomski; Georg Lattner; Torben Schmidt; Jürgen Römisch
Journal:  BioDrugs       Date:  2017-04       Impact factor: 5.807

2.  Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy.

Authors:  David R Cornblath; Pieter A van Doorn; Hans-Peter Hartung; Ingemar S J Merkies; Hans D Katzberg; Doris Hinterberger; Elisabeth Clodi
Journal:  Brain       Date:  2022-04-29       Impact factor: 13.501

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.